Drug Profile
Ambrisentan - Gilead Sciences/GSK
Alternative Names: BSF 208075; GSK 1325760; GSK1325760A; Letairis; VolibrisLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Knoll
- Developer Gilead Sciences; GSK
- Class Antihypertensives; Phenylpropionates; Pyridazines; Small molecules
- Mechanism of Action Endothelin A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Pulmonary arterial hypertension
- Discontinued Idiopathic pulmonary fibrosis; Pulmonary hypertension
Most Recent Events
- 17 Dec 2019 GlaxoSmithKline completes a phase I trial in Hypertension (In volunteers) in United Kingdom (NCT04095286)
- 30 Sep 2019 GlaxoSmithKline initiates a phase I trial for Pulmonary arterial hypertension (In volunteers) in the United Kingdom (PO, Tablet) (NCT04095286)
- 19 Sep 2019 GlaxoSmithKline plans a phase I trial in healthy volunteers (PO) (NCT04095286)